These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23550257)

  • 1. Duration of treatment for osteoporosis.
    Idolazzi L; Fassio A; Gatti D; Tamanini S; Viapiana O; Rossini M; Adami S
    Reumatismo; 2013 Mar; 65(1):22-35. PubMed ID: 23550257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in the treatment of osteoporosis.
    Diab DL; Watts NB
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bisphosphonates treatment in patients with osteoporosis].
    Rizzoli R
    Ther Umsch; 2012 Mar; 69(3):173-81. PubMed ID: 22403110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bisphosphonate treatment against breast cancer with bone metastases].
    Kohno N
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():575-81. PubMed ID: 17682213
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2014 Mar; 24(3):401-6. PubMed ID: 24576937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment and prevention of osteoporosis in patients with decreased renal function].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
    Hosoi T
    Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rational approach to evidence gaps in the management of osteoporosis.
    Rosen CJ; Brown SA
    Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
    Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
    Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate holidays.
    Reid IR
    Drug Ther Bull; 2021 Mar; 59(3):35-36. PubMed ID: 33627350
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
    Aspray TJ; Francis RM
    Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment holidays in patients with postmenopausal osteoporosis: whom and when?
    Reyes García R; García Martín A; Muñoz-Torres M
    Endocrinol Nutr; 2012 Dec; 59(10):573-4. PubMed ID: 23031434
    [No Abstract]   [Full Text] [Related]  

  • 18. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
    Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
    Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.